Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.48 |
| ▸ | KIT | P10721 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011645 | 0.90 | RXFP1 (0.48) | HDAC1RXFP1KITKDRABL1 | |
| SCHEMBL5900593 | 0.90 | KDR (0.54) | HDAC1RXFP1KITKDRABL1 | |
| SCHEMBL5900455 | 0.88 | RXFP1 (0.47) | HDAC1RXFP1KITKDRABL1 | |
| SCHEMBL1011475 | 0.87 | RXFP1 (0.45) | HDAC1RXFP1KITKDRABL1 | |
| Hydrochloric Acid SCHEMBL4036310 | 0.87 | RXFP1 (0.47) | HDAC1RXFP1KITKDRABL1 | |
| SCHEMBL1039583 | 0.85 | RXFP1 (0.68) | RXFP1KITKDRABL1EGFR | |
| Hydrochloric Acid SCHEMBL1041443 | 0.85 | RXFP1 (0.67) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL5900491 | 0.84 | HDAC1 (0.46) | HDAC1RXFP1KITKDRABL1 | |
| SCHEMBL5900585 | 0.83 | ABL1 (0.57) | KITABL1EGFRCSF1RBRAF | |
| SCHEMBL1037851 | 0.83 | HDAC1 (0.46) | HDAC1RXFP1KITKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | claimed |
| EP-1572686-B1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | HDAC1 487/4885RXFP1 2090/4885KIT 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.